Replies to post #3684 on ImClone Systems Inc (formerly IMCL)

[biophud]

Jbog--Thanks for the info. IMO it is a good sign when multiple independent groups come to the same conclusion--further validating IGFR-1 as a good therapeutic target. I was not aware that Pfizer's AB is an IgG2. Not sure why Pfizer decided to go with an IgG2 AB.

Any insights on how IMCL plans to develop its pipeline. Combination trials with Erbitux (?) Trials on patients who have failed Erbitux (?) Frontlineline trials in combination chemo/radiation?

I do not think that Xenomouse ABs from ABGX are all IgG2. My understanding is that the Xenomouse platform can produce all isotypes (Chir-12.12 is an example of an IgG1 AB from the Xenomouse platform).

Regards,

biophud